Henry L. Gomez
Henry L. Gómez
Department of Medicine
Instituto Nacional de Enfermedades Neoplásicas
Av. Angamos Este 2520
Name/email consistency: high
- Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Gómez, H.L., Samanéz, C., Campana, F., Neciosup, S.P., Vera, L., Casanova, L., Leon, J., Flores, C., de Mendoza, F.H., Casteñeda, C.A., Pinto, J.A., Vallejos, C.S. Hematol. Oncol. Stem. Cell. Ther (2012)
- Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Gómez, H.L., Pinto, J.A., Olivera, M., Vidaurre, T., Doimi, F.D., Vigil, C.E., Velarde, R.G., Abugattas, J.E., Alarcón, E., Vallejos, C.S. Breast (2011)
- Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Gómez, H.L., Castañeda, C.A., Vigil, C.E., Vidaurre, T., Velarde, R.G., Cruz, W.R., Pinto, J.A., Suazo, J.F., Garcés, M.R., Neciosup, S.P., Vallejos, C.S. Hematol. Oncol. Stem. Cell. Ther (2010)
- Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. Gomez, H.L., Doval, D.C., Chavez, M.A., Ang, P.C., Aziz, Z., Nag, S., Ng, C., Franco, S.X., Chow, L.W., Arbushites, M.C., Casey, M.A., Berger, M.S., Stein, S.H., Sledge, G.W. J. Clin. Oncol. (2008)
- A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Gomez, H.L., Santillana, S.L., Vallejos, C.S., Velarde, R., Sanchez, J., Wang, X., Bauer, N.L., Hockett, R.D., Chen, V.J., Niyikiza, C., Hanauske, A.R. Clin. Cancer Res. (2006)
